Hasegawa Y, Nakano S, Hashizume T, Noguchi A, Ibuka K, Kasugai H, Kojima J, Ishigami S
Department of Nuclear Medicine, Center for Adults Diseases, Osaka, Japan.
Clin Nucl Med. 1989 Jul;14(7):526-31. doi: 10.1097/00003072-198907000-00011.
Delayed imaging was performed after the intravenous administration of Tc-99m DEIDA and Tc-99m PMT in 18 patients with hepatocellular carcinoma. Using Tc-99m DEIDA imaging, sharp uptake by liver tumors was observed in four patients (22%), but the uptake was similar to that of the surrounding normal liver in eight patients (44%). Using Tc-99m PMT imaging, the uptake by the tumor was notable in ten patients (56%) and normal in two (11%). Tc-99m PMT and Tc-99m DEIDA were both concentrated in hepatocellular carcinomas, but the former showed intense uptakes more frequently, and thus is suggested to be useful in the diagnosis of hepatocellular carcinoma.
对18例肝细胞癌患者静脉注射锝-99m二乙基乙酰苯胺（Tc-99m DEIDA）和锝-99m吡哆醛-5-甲基色氨酸（Tc-99m PMT）后进行延迟显像。使用Tc-99m DEIDA显像时，4例患者（22%）的肝肿瘤摄取明显，但8例患者（44%）的摄取与周围正常肝脏相似。使用Tc-99m PMT显像时，10例患者（56%）的肿瘤摄取明显，2例患者（11%）正常。Tc-99m PMT和Tc-99m DEIDA均在肝细胞癌中浓聚，但前者更频繁地显示出强烈摄取，因此提示其在肝细胞癌诊断中有用。
